Home
RYTM
RYTM News

Latest Rhythm Pharmaceuticals Inc. (RYTM) News on May 10, 2025

Rhythm Pharmaceuticals Inc (RYTM) Q1 2025 Earnings Call Highlights: Strong IMCIVREE Sales and ...

GuruFocus.com

2 days ago

Rhythm Pharmaceuticals Inc (RYTM) Q1 2025 Earnings Call Highlights: Strong IMCIVREE Sales and ...

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Lags Revenue Estimates

Zacks

3 days ago

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Lags Revenue Estimates

MT Newswires

3 days ago

Rhythm Pharmaceuticals' Q1 Net Loss Narrows, Revenue Increases

Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update

GlobeNewswire

3 days ago

Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

GlobeNewswire

4 days ago

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

MT Newswires

8 days ago

Rhythm Pharmaceuticals Insider Sold Shares Worth $438,946, According to a Recent SEC Filing

MT Newswires

8 days ago

Rhythm Pharmaceuticals Insider Sold Shares Worth $457,663, According to a Recent SEC Filing

Analysts Estimate Wave Life Sciences (WVE) to Report a Decline in Earnings: What to Look Out for

Zacks

8 days ago

Analysts Estimate Wave Life Sciences (WVE) to Report a Decline in Earnings: What to Look Out for

Will Rhythm Pharmaceuticals, Inc. (RYTM) Report Negative Earnings Next Week? What You Should Know

Zacks

9 days ago

Will Rhythm Pharmaceuticals, Inc. (RYTM) Report Negative Earnings Next Week? What You Should Know

Rhythm Pharmaceuticals (RYTM) Moves 5.2% Higher: Will This Strength Last?

Zacks

14 days ago

Rhythm Pharmaceuticals (RYTM) Moves 5.2% Higher: Will This Strength Last?

Rhythm Pharmaceuticals to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025

GlobeNewswire

17 days ago

Rhythm Pharmaceuticals to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025

MT Newswires

a month ago

Rhythm Pharmaceuticals Insider Sold Shares Worth $1,082,497, According to a Recent SEC Filing

MT Newswires

a month ago

Rhythm Pharmaceuticals Insider Sold Shares Worth $1,248,490, According to a Recent SEC Filing

Rhythm Pharmaceuticals Stock Earns RS Rating Upgrade

Investor's Business Daily

a month ago

Rhythm Pharmaceuticals Stock Earns RS Rating Upgrade

5 Stocks in Nasdaq ETF Fueling Index's Big Comeback Since 2008

Zacks

a month ago

5 Stocks in Nasdaq ETF Fueling Index's Big Comeback Since 2008

RYTM Stock Rises 17% on Meeting Goals in Hypothalamic Obesity Study

Zacks

a month ago

RYTM Stock Rises 17% on Meeting Goals in Hypothalamic Obesity Study

MT Newswires

a month ago

Morgan Stanley Raises Price Target on Rhythm Pharmaceuticals to $77 From $72, Keeps Overweight Rating

Rhythm Pharmaceuticals (RYTM) Surges 17.1%: Is This an Indication of Further Gains?

Zacks

a month ago

Rhythm Pharmaceuticals (RYTM) Surges 17.1%: Is This an Indication of Further Gains?

Exploring 3 High Growth Tech Stocks In The US Market

Simply Wall St.

a month ago

Exploring 3 High Growth Tech Stocks In The US Market

This Obesity Drug Just Crushed Expectations -- And Sent One Biotech Stock Soaring 14.5%

GuruFocus.com

a month ago

This Obesity Drug Just Crushed Expectations -- And Sent One Biotech Stock Soaring 14.5%

Rhythm seeks market expansion for Imcivree following Phase III victory

Clinical Trials Arena

a month ago

Rhythm seeks market expansion for Imcivree following Phase III victory

Rhythm Pharmaceuticals Weight Loss Drug Study Shows Significant BMI Reduction For Rare Type Of Obesity Disorder

Benzinga

a month ago

Rhythm Pharmaceuticals Weight Loss Drug Study Shows Significant BMI Reduction For Rare Type Of Obesity Disorder

Obesity drug data helps Rhythm defy market slide

BioPharma Dive

a month ago

Obesity drug data helps Rhythm defy market slide

MT Newswires

a month ago

Rhythm Pharmaceuticals' Obesity Treatment Meets Main Goal in Phase 3 Study, Shares Rise

Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity

GlobeNewswire

a month ago

Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients with Acquired Hypothalamic Obesity

GlobeNewswire

a month ago

Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients with Acquired Hypothalamic Obesity

MT Newswires

2 months ago

Rhythm Pharmaceuticals Regains Licensing Rights to Imcivree Obesity Drug

Is Rhythm Pharmaceuticals (RYTM) a Worst High-Risk High-Reward Growth Stock to Buy?

Insider Monkey

2 months ago

Is Rhythm Pharmaceuticals (RYTM) a Worst High-Risk High-Reward Growth Stock to Buy?

Rhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE® (setmelanotide) in China with Termination of Agreement with RareStone Ltd.

GlobeNewswire

2 months ago

Rhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE® (setmelanotide) in China with Termination of Agreement with RareStone Ltd.

MT Newswires

2 months ago

Rhythm Gets Orphan Drug Label for Setmelanotide in Japan

Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan

GlobeNewswire

2 months ago

Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan

MT Newswires

2 months ago

Rhythm Pharmaceuticals Insider Sold Shares Worth $3,861,272, According to a Recent SEC Filing

Rhythm Pharmaceuticals and Raymond A. Wood Foundation Announce Research Collaboration

GlobeNewswire

2 months ago

Rhythm Pharmaceuticals and Raymond A. Wood Foundation Announce Research Collaboration

US High Growth Tech Stocks to Watch in March 2025

Simply Wall St.

2 months ago

US High Growth Tech Stocks to Watch in March 2025

We Think Rhythm Pharmaceuticals (NASDAQ:RYTM) Can Afford To Drive Business Growth

Simply Wall St.

2 months ago

We Think Rhythm Pharmaceuticals (NASDAQ:RYTM) Can Afford To Drive Business Growth

Rhythm Pharmaceuticals Full Year 2024 Earnings: Revenues Beat Expectations, EPS In Line

Simply Wall St.

2 months ago

Rhythm Pharmaceuticals Full Year 2024 Earnings: Revenues Beat Expectations, EPS In Line

Rhythm Pharmaceuticals Inc (RYTM) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...

GuruFocus.com

2 months ago

Rhythm Pharmaceuticals Inc (RYTM) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...

Thomson Reuters StreetEvents

2 months ago

Q4 2024 Rhythm Pharmaceuticals Inc Earnings Call

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Tops Revenue Estimates

Zacks

2 months ago

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Tops Revenue Estimates

MT Newswires

2 months ago

Rhythm Pharmaceuticals Q4 Loss Widens, Revenue Increases

Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update

GlobeNewswire

2 months ago

Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update

These Biotech Stocks Aren't Profitable But Still Make Elite IBD 50

Investor's Business Daily

3 months ago

These Biotech Stocks Aren't Profitable But Still Make Elite IBD 50

Cytokinetics (CYTK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Zacks

3 months ago

Cytokinetics (CYTK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on Wednesday, February 26, 2025

GlobeNewswire

3 months ago

Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on Wednesday, February 26, 2025

Rhythm Pharmaceuticals to Present at Oppenheimer Annual Healthcare Life Sciences Conference in February

GlobeNewswire

3 months ago

Rhythm Pharmaceuticals to Present at Oppenheimer Annual Healthcare Life Sciences Conference in February

Wall Street Analysts Think Rhythm Pharmaceuticals (RYTM) Could Surge 26.36%: Read This Before Placing a Bet

Zacks

3 months ago

Wall Street Analysts Think Rhythm Pharmaceuticals (RYTM) Could Surge 26.36%: Read This Before Placing a Bet

Exploring High Growth Tech Stocks in January 2025

Simply Wall St.

4 months ago

Exploring High Growth Tech Stocks in January 2025

Rhythm Pharmaceuticals (RYTM) Soars 5.5%: Is Further Upside Left in the Stock?

Zacks

4 months ago

Rhythm Pharmaceuticals (RYTM) Soars 5.5%: Is Further Upside Left in the Stock?

Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2024 Net Product Revenues, Pipeline Advancements and Upcoming Milestones

GlobeNewswire

4 months ago

Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2024 Net Product Revenues, Pipeline Advancements and Upcoming Milestones

Jefferies starts Rhythm Pharmaceuticals with Buy on obesity potential

TipRanks

4 months ago

Jefferies starts Rhythm Pharmaceuticals with Buy on obesity potential

MT Newswires

4 months ago

Jefferies Initiates Rhythm Pharmaceuticals at Buy With $80 Price Target

Exploring 3 High Growth Tech Stocks In The United States

Simply Wall St.

5 months ago

Exploring 3 High Growth Tech Stocks In The United States

Rhythm Pharmaceuticals' (NASDAQ:RYTM) investors will be pleased with their incredible 370% return over the last three years

Simply Wall St.

5 months ago

Rhythm Pharmaceuticals' (NASDAQ:RYTM) investors will be pleased with their incredible 370% return over the last three years

MT Newswires

5 months ago

Rhythm Pharmaceuticals Gains FDA Approval for Expanded IMCIVREE Use

Rhythm Pharmaceuticals' Obesity Treatments Target Less Crowded Space, Analyst Sees Long-Term Potential

Benzinga

5 months ago

Rhythm Pharmaceuticals' Obesity Treatments Target Less Crowded Space, Analyst Sees Long-Term Potential

Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients as Young as 2 Years Old

GlobeNewswire

5 months ago

Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients as Young as 2 Years Old

MT Newswires

5 months ago

Oppenheimer Initiates Coverage on Rhythm Pharmaceuticals With Outperform Rating, $76 Price Target

Rhythm Pharmaceuticals price target raised to $75 from $64 at JMP Securities

TipRanks

5 months ago

Rhythm Pharmaceuticals price target raised to $75 from $64 at JMP Securities

MT Newswires

5 months ago

Rhythm Pharmaceuticals Says Imcivree Receives Expanded Marketing Authorization in UK

Rhythm Pharmaceuticals Announces ▼ IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency to include Children as Young as 2 Years Old

GlobeNewswire

5 months ago

Rhythm Pharmaceuticals Announces ▼ IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency to include Children as Young as 2 Years Old

Biotech Stock Attempts To End Losing Streak, Lands Back in Buy Zone

Investor's Business Daily

6 months ago

Biotech Stock Attempts To End Losing Streak, Lands Back in Buy Zone

Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide

GlobeNewswire

6 months ago

Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide

Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in The Lancet Diabetes & Endocrinology

GlobeNewswire

6 months ago

Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in The Lancet Diabetes & Endocrinology

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

GlobeNewswire

6 months ago

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

High Growth Tech Stocks Featuring Three Prominent US Companies

Simply Wall St.

6 months ago

High Growth Tech Stocks Featuring Three Prominent US Companies

Rhythm Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations

Simply Wall St.

6 months ago

Rhythm Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations

Rhythm Pharmaceuticals Inc (RYTM) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...

GuruFocus.com

6 months ago

Rhythm Pharmaceuticals Inc (RYTM) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

GlobeNewswire

6 months ago

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Tops Revenue Estimates

Zacks

6 months ago

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Tops Revenue Estimates

Rhythm Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Update

GlobeNewswire

6 months ago

Rhythm Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Update

Rhythm Pharmaceuticals Announces Five New Data Presentations at ObesityWeek® 2024

GlobeNewswire

6 months ago

Rhythm Pharmaceuticals Announces Five New Data Presentations at ObesityWeek® 2024

Will Allogene Therapeutics (ALLO) Report Negative Earnings Next Week? What You Should Know

Zacks

6 months ago

Will Allogene Therapeutics (ALLO) Report Negative Earnings Next Week? What You Should Know

Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Zacks

6 months ago

Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

ImmunityBio (IBRX) Soars 26.4%: Is Further Upside Left in the Stock?

Zacks

6 months ago

ImmunityBio (IBRX) Soars 26.4%: Is Further Upside Left in the Stock?

Rhythm Pharmaceuticals and Axovia Therapeutics Announce Joint Research Collaboration in Bardet-Biedl Syndrome

GlobeNewswire

7 months ago

Rhythm Pharmaceuticals and Axovia Therapeutics Announce Joint Research Collaboration in Bardet-Biedl Syndrome

Rhythm Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 5, 2024

GlobeNewswire

7 months ago

Rhythm Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 5, 2024

MT Newswires

7 months ago

Guggenheim Initiates Coverage on Rhythm Pharmaceuticals With Buy Rating, $70 Price Target

High Growth Tech Stocks to Watch in October 2024

Simply Wall St.

7 months ago

High Growth Tech Stocks to Watch in October 2024

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

GlobeNewswire

7 months ago

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

Rhythm Pharmaceuticals, Inc. (RYTM): Short Seller Sentiment is Bearish

Insider Monkey

8 months ago

Rhythm Pharmaceuticals, Inc. (RYTM): Short Seller Sentiment is Bearish

Strength Seen in Rhythm Pharmaceuticals (RYTM): Can Its 7.4% Jump Turn into More Strength?

Zacks

8 months ago

Strength Seen in Rhythm Pharmaceuticals (RYTM): Can Its 7.4% Jump Turn into More Strength?

MT Newswires

8 months ago

HC Wainwright Initiates Rhythm Pharmaceuticals at Buy

MT Newswires

8 months ago

Rhythm Pharmaceuticals Shares Rise After JMP Securities Initiates Coverage at Outperform

MT Newswires

8 months ago

JMP Securities Initiates Rhythm Pharmaceuticals at Outperform

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

GlobeNewswire

8 months ago

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

Biotech Stock Near Buy Point Amid Impressive Sales Track Record

Investor's Business Daily

8 months ago

Biotech Stock Near Buy Point Amid Impressive Sales Track Record

Four Biotech Stocks Rally Toward Buy Points As Funds Load Up

Investor's Business Daily

8 months ago

Four Biotech Stocks Rally Toward Buy Points As Funds Load Up

Biotech Stock Roundup: REGN's Drug Approval, LXRX, RYTM Stocks Gain on Update & More

Zacks

8 months ago

Biotech Stock Roundup: REGN's Drug Approval, LXRX, RYTM Stocks Gain on Update & More

High Growth Tech Stocks To Watch In August 2024

Simply Wall St.

8 months ago

High Growth Tech Stocks To Watch In August 2024

MT Newswires

8 months ago

Sector Update: Health Care Stocks Ease in Afternoon Trading

MT Newswires

8 months ago

Rhythm Pharmaceuticals Says US FDA Accepts its Supplemental New Drug Application for Imcivree

Rhythm Pharmaceuticals Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for IMCIVREE® (setmelanotide) in Patients as Young as 2 years old

GlobeNewswire

8 months ago

Rhythm Pharmaceuticals Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for IMCIVREE® (setmelanotide) in Patients as Young as 2 years old

Rhythm Pharmaceuticals to Present at Wells Fargo Healthcare Conference in September

GlobeNewswire

8 months ago

Rhythm Pharmaceuticals to Present at Wells Fargo Healthcare Conference in September

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

GlobeNewswire

9 months ago

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

Analysts Are Updating Their Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Estimates After Its Second-Quarter Results

Simply Wall St.

9 months ago

Analysts Are Updating Their Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Estimates After Its Second-Quarter Results

MT Newswires

9 months ago

Rhythm Pharmaceuticals' Q2 Net Loss Narrows, Revenue Rises

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates

Zacks

9 months ago

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates

Rhythm Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Update

GlobeNewswire

9 months ago

Rhythm Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Update

MT Newswires

9 months ago

Rhythm Pharmaceuticals Gets European Commission's Expanded Authorization for Obesity Drug

Rhythm Pharmaceuticals Announces European Commission Expands ▼IMCIVREE® (setmelanotide) Marketing Authorization to include Children as Young as 2 Years Old

GlobeNewswire

9 months ago

Rhythm Pharmaceuticals Announces European Commission Expands ▼IMCIVREE® (setmelanotide) Marketing Authorization to include Children as Young as 2 Years Old

Share on Social Networks: